Tags : Antibodies

Biotech

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against

Shots: AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration The expanded collaboration will utilize AbCellera’s technology stack, which includes Trianni Mouse and OrthoMab protein engineering platform AbCellera will generate panels of Abs against up to 8 new targets across multiple indications, selected by Gilead […]Read More

Viewpoints

ViewPoints Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the

In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it works on SARS-CoV-2. Shots: ADG2 showed broad and potent neutralizing activity against SARS-CoV and two SARS-related coronaviruses currently known to be circulating in bat populations (WIV-1 and SHC014) The company […]Read More

Biotech COVID-19

Biogen Collaborates with Vir Biotechnology to Develop Antibodies Against COVID-19

Shots: Biogen has signed a letter of intent with Vir to develop & manufacture mAb targeting COVID-1 and have started working together due to the urgency of the crisis while a development & manufacturing agreement is being negotiated Following the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical […]Read More

Biotech

WuXi Biologics and Vir Biotechnology Collaborate for the Global Development

Shots: The companies will jointly develop, manufacture & commercialize Vir’s Ab. WuXi Biologics will conduct cell-line development, process & formulation development and initial manufacturing for clinical development Following the regulatory approvals, Wuxi Biologics to get rights to commercialize therapies in Greater China while Vir retain WW commercial rights for the therapies The collaboration accelerates the […]Read More